A High Throughput Human Tumor Modeling Technology for Cancer Drug Discovery

Information

  • Research Project
  • 10330116
  • ApplicationId
    10330116
  • Core Project Number
    R33CA225549
  • Full Project Number
    3R33CA225549-03S2
  • Serial Number
    225549
  • FOA Number
    PA-20-227
  • Sub Project Id
  • Project Start Date
    6/1/2019 - 5 years ago
  • Project End Date
    5/31/2022 - 2 years ago
  • Program Officer Name
    SORG, BRIAN S
  • Budget Start Date
    6/1/2021 - 3 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
    S2
  • Award Notice Date
    6/17/2021 - 3 years ago
Organizations

A High Throughput Human Tumor Modeling Technology for Cancer Drug Discovery

Project Summary Fisetin is a naturally-occurring phytochemical abundantly found in vegetables and fruits as the coloring agent. Preclinical studies have shown that fisetin offers anti-inflammatory and anti-oxidant benefits and protective effects against chronic diseases. Due to its significant benefits, consumption of fisetin as a dietary supplement is currently being studied in a clinical trial. Guided by our recent studies that showed fisetin significantly downregulates oncogenic signaling in breast cancer cells, we hypothesized that fisetin has chemopreventive effects against processes that are essential to breast cancer metastasis. Thus, using fisetin as a supplement may have preventive benefits against metastatic progression and significantly improve outcomes for patients. Because breast cancer metastasis occurs often very early and even before primary tumors are detected, preventing pro-metastatic processes is essential to improve outcomes for patients. We will test our hypothesis using our three-dimensional organotypic breast tumor model and a humanized mouse model of breast cancer, to study chemopreventive effects of fisetin on proliferation, epithelial-to-mesenchymal transition, and local invasion of cancer cells. Through phenotypic and mechanistic studies, we aim to demonstrate that fisetin supplementation will have benefits against breast tumor growth and frequencies of local and distant metastasis. In addition, our systematic studies in this project will help broaden investigations of dietary supplements as chemopreventive agents to block progression of breast cancer and other malignancies.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R33
  • Administering IC
    CA
  • Application Type
    3
  • Direct Cost Amount
    119599
  • Indirect Cost Amount
    46800
  • Total Cost
    166399
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
    OD:166399\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF AKRON
  • Organization Department
    BIOMEDICAL ENGINEERING
  • Organization DUNS
    045207552
  • Organization City
    AKRON
  • Organization State
    OH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    443250001
  • Organization District
    UNITED STATES